What is a Sertoli-Leydig cell tumour?
A Sertoli-Leydig cell tumour (SLCT) is a rare tumour of the ovary that belongs to the group called sex cord-stromal tumours. These tumours grow from the supporting and hormone-making tissue of the ovary rather than from its surface lining.
SLCTs contain cells that look like the Sertoli and Leydig cells of the testis. Because of this, many of them make male hormones (androgens), especially testosterone.
They make up less than 0.5% of all ovarian tumours. Most occur in teenagers and young women, with an average age at diagnosis of about 25.
The hormones can cause excess body hair, acne, a deeper voice and missed periods. These changes often lead a young woman to see a doctor before the tumour itself causes any problems.
Many SLCTs are linked with changes in the DICER1 gene. In some girls and women this change is inherited and is part of DICER1 syndrome, which also raises the risk of other tumours.
Most SLCTs are found while still confined to one ovary. Surgery alone usually cures them, and fertility can often be preserved.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Ovarian sex cord-stromal tumour |
| How common | Less than 0.5% of ovarian tumours |
| Typical age | Mostly 10-35; median about 25 |
| Hormones | About a third to a half cause signs of male hormone excess |
| Sides affected | Almost always one ovary |
| Stage at diagnosis | Over 95% confined to the ovary (stage I) |
| Key gene | DICER1 (often in younger patients); FOXL2 in some older women |
| Main treatment | Surgery, often fertility-sparing; chemotherapy for high-risk tumours |
| Outlook | Excellent for well-differentiated stage I tumours |
2. Types of Sertoli-Leydig cell tumour
The World Health Organization groups SLCTs by how closely the cells resemble normal testicular tissue. This is called differentiation, and it is the most important guide to behaviour.
| Type | Microscope features | Behaviour |
|---|---|---|
| Well differentiated | Neat hollow tubules of Sertoli cells with clusters of Leydig cells | Benign in almost all cases |
| Moderately differentiated | Cords and nests of Sertoli cells in a cellular background, with Leydig cells | Most common type; recurs in about 1 in 10 |
| Poorly differentiated | Sheets of immature spindle cells, resembling a sarcoma | Recurs or spreads in about half or more |
| Retiform pattern | Slit-like spaces resembling the rete testis | Higher risk; often in younger girls |
| With heterologous elements | Contains other tissue types, such as gut-type mucinous glands, cartilage or muscle | Risk depends on the tissue; immature muscle or cartilage is high risk |
In a landmark study of 207 cases, none of the well-differentiated tumours behaved in a malignant way. Most of the poorly differentiated ones did (Young and Scully, 1985).
3. Causes and risk factors
Most SLCTs have no obvious cause. Research over the last decade has identified clear genetic groups, however.
| Group | Typical patient | Notes |
|---|---|---|
| DICER1-mutated | Girls and young women, median about 15-20 | Usually moderately or poorly differentiated; may be retiform or contain heterologous elements |
| FOXL2-mutated | Women after the menopause | Usually moderately or poorly differentiated |
| Neither gene changed | Middle-aged women | Usually well differentiated |
This grouping was described by Karnezis et al. (2019). DICER1 changes were first found in these tumours in 2012 (Heravi-Moussavi et al., 2012).
DICER1 syndrome
In a proportion of patients, the DICER1 change is present in every cell of the body because it was inherited or arose very early in life. This is called DICER1 syndrome (DICER1-related tumour predisposition).
People with DICER1 syndrome have a higher chance of:
- Pleuropulmonary blastoma, a rare lung tumour of young children
- Multinodular goitre and thyroid cancer
- Cystic nephroma, a kidney tumour
- Embryonal rhabdomyosarcoma of the cervix
- Rare tumours of the eye, nose and brain
For this reason, genetic counselling and testing for DICER1 are recommended for everyone diagnosed with an SLCT (Schultz et al., 2018). Family members who carry the change can be offered surveillance, including regular pelvic ultrasound for girls and women.
4. How does it look
The tumour itself
An SLCT usually forms a solid, smooth, lobulated mass in one ovary. The average size is around 12-15 cm, although tumours range from a few centimetres to over 30 cm.
The cut surface is typically yellow, tan or grey-white and fleshy. Larger and less differentiated tumours may contain cysts, bleeding and areas of dead tissue (necrosis).
Retiform tumours and those with mucinous heterologous elements often look more cystic or spongy. Both ovaries are involved in fewer than 2% of cases.
On scans
| Scan | What doctors may see |
|---|---|
| Pelvic ultrasound | A solid or mainly solid mass in one ovary, often with good blood flow |
| MRI | A well-defined solid mass; helps tell it apart from other ovarian tumours |
| CT | Used if there is concern about spread or for planning surgery |
Visible changes in the body
The tumour cannot usually be seen from the outside. Its hormone effects can be very noticeable, however:
| Body change | Description |
|---|---|
| Hirsutism | Coarse, dark hair on the face, chest, abdomen or back |
| Acne | New or worsening spots on the face and back |
| Hair loss | Thinning at the temples or crown (male-pattern balding) |
| Voice changes | Deepening or hoarseness of the voice |
| Clitoral enlargement | Clitoromegaly from high testosterone |
| Body shape | Increased muscle bulk and smaller breasts |
5. Symptoms
Symptoms come from two sources: the hormones the tumour makes and the size of the mass itself. Some tumours make no hormones and are found only because of pain or swelling.
Hormone-related symptoms
About a third to a half of women have signs of virilisation (male hormone excess):
- Missed or irregular periods, or periods stopping altogether (amenorrhoea)
- Excess hair growth on the face and body
- Acne and oily skin
- Deepening of the voice
- Hair loss on the scalp
- Enlarged clitoris
- Breast shrinkage
These changes usually develop over months, which can lead to a delay in diagnosis. Rapidly developing male hormone signs in a girl or woman should always be investigated.
A small number of SLCTs produce oestrogen instead. This can cause irregular bleeding, early puberty in young girls or bleeding after the menopause.
Symptoms from the mass
- Pain or discomfort in the lower abdomen or pelvis
- Swelling or a lump in the abdomen
- Sudden severe pain if the ovary twists (torsion) or the tumour bursts
- Pressure on the bladder or bowel
When to see a doctor
See a doctor if you notice new excess hair growth, a deepening voice or periods stopping without explanation, especially if these changes appear quickly. Persistent pelvic pain or abdominal swelling should also be checked.
6. Diagnosis
| Test | Purpose |
|---|---|
| Medical history and examination | Looks for signs of male hormone excess and a pelvic mass |
| Testosterone and androstenedione | Often raised; very high testosterone suggests a hormone-making tumour |
| Inhibin and AMH | Markers of sex cord-stromal tumours; useful for follow-up |
| AFP (alpha-fetoprotein) | Sometimes raised, especially in retiform tumours or those with liver-type tissue |
| Pregnancy test, CA125, LDH, hCG | Help rule out other ovarian tumours |
| Pelvic ultrasound and MRI | Locate and describe the mass |
| Surgery and pathology | Confirms the diagnosis, type and stage |
| DICER1 testing | On the tumour and in blood, to check for an inherited change |
Conditions that can look similar
Other causes of male hormone excess include polycystic ovary syndrome, adrenal tumours, congenital adrenal hyperplasia and other ovarian tumours such as steroid cell tumours.
Under the microscope, SLCTs must be told apart from granulosa cell tumours, endometrioid carcinoma and yolk sac tumours. Special stains such as inhibin, calretinin, SF-1 and FOXL2 help the pathologist.
7. Staging
SLCTs are staged with the same FIGO system used for other ovarian tumours.
| Stage | Meaning | How often |
|---|---|---|
| IA | One ovary, capsule intact | Most cases |
| IC | One ovary, but capsule ruptured, tumour on the surface or cells in fluid | A minority; ruptured tumours carry more risk |
| II-IV | Spread into the pelvis, abdomen or beyond | Uncommon (under 5%) |
8. Treatment
Treatment is best planned by a gynaecological oncology team with experience of rare ovarian tumours. Recommendations follow the ESMO guidelines for non-epithelial ovarian cancer (Ray-Coquard et al., 2018).
Surgery
| Situation | Usual surgery |
|---|---|
| Young woman, stage IA | Removal of the affected ovary and fallopian tube only (fertility-sparing) |
| Woman who has completed her family | Removal of both ovaries, tubes and womb may be offered |
| Staging | Washings, inspection of the abdomen and biopsies; lymph node removal is usually not needed |
| Spread disease | Removal of all visible tumour where possible |
Keeping the other ovary and the womb allows most young women to have normal periods and pregnancies after treatment.
Chemotherapy
Chemotherapy is not needed for most well-differentiated and moderately differentiated stage IA tumours.
| Situation | Chemotherapy |
|---|---|
| Well or moderately differentiated, stage IA | None; follow-up only |
| Poorly differentiated, retiform or high-risk heterologous elements | Platinum-based chemotherapy often recommended |
| Ruptured tumour (stage IC) | Considered, especially with poor differentiation |
| Stage II-IV or recurrence | Platinum-based chemotherapy, usually BEP (bleomycin, etoposide, cisplatin) |
Return of normal hormone levels
After removal of the tumour, testosterone falls to normal within days to weeks. Periods usually return within a few months.
Acne and excess hair improve slowly, and cosmetic hair removal can help. A deepened voice often stays partly lower, and some clitoral enlargement may remain.
9. Outlook (prognosis)
The outlook for most women with an SLCT is excellent. Overall, about 90% or more are alive and well long term.
| Factor | Effect on outlook |
|---|---|
| Well differentiated | Almost always cured |
| Moderately differentiated | Usually cured; small risk of recurrence |
| Poorly differentiated | Recurrence or spread in about half or more |
| Retiform or immature heterologous elements | Higher risk |
| Rupture of the tumour | Higher risk of recurrence |
| Stage above I | Poor outlook, though chemotherapy can help |
When SLCTs come back, it is usually early, within the first 1-2 years, and mostly in the pelvis or abdomen (Gui et al., 2012). Recurrent disease is harder to treat.
10. Follow-up
| Time after surgery | Typical follow-up |
|---|---|
| Years 1-2 | Every 3-4 months: symptoms, examination, testosterone, inhibin and AFP if they were raised, pelvic ultrasound |
| Years 3-5 | Every 6 months |
| After 5 years | Yearly, especially for DICER1 carriers |
Women with DICER1 syndrome also need surveillance for other tumours. This includes thyroid checks, and their relatives may be offered testing.
11. Living with and after an SLCT
The physical changes caused by male hormones can be distressing, particularly for teenagers. Many young women feel self-conscious about facial hair, acne or a deeper voice, and these feelings are completely understandable.
Several kinds of practical support can help:
| Concern | Possible help |
|---|---|
| Excess hair | Laser hair removal or electrolysis once hormone levels are normal |
| Acne | Standard skin treatments from a GP or dermatologist |
| Voice changes | Speech and voice therapy |
| Fertility worries | A fertility specialist can review egg reserve, especially if chemotherapy was given |
| Worry about the future | Psychological support, teenage and young adult cancer services, patient groups |
Chemotherapy with BEP can affect hearing, the lungs and fertility. These effects are checked during and after treatment.
12. Frequently asked questions
| Question | Answer |
|---|---|
| Is a Sertoli-Leydig cell tumour cancer? | It ranges from benign to malignant depending on its type; most behave in a benign way |
| Will the extra hair go away? | It slowly improves once testosterone falls, but laser or other hair removal may still be needed |
| Can I have children after treatment? | Usually yes, as most young women keep their womb and other ovary |
| Does pregnancy increase the risk of recurrence? | There is no good evidence that it does |
| Should my family be tested? | If you carry an inherited DICER1 change, relatives can be offered testing |
13. Questions to ask your care team
- What type and stage is my tumour?
- Was the tumour ruptured before or during surgery?
- Do I need chemotherapy?
- Can I keep my fertility?
- Should I have DICER1 genetic testing?
- Which blood tests and scans will I have during follow-up?
Resources
- Young, R.H. and Scully, R.E. (1985) ‘Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases’, American Journal of Surgical Pathology, 9(8), pp. 543-569.
- Heravi-Moussavi, A. et al. (2012) ‘Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers’, New England Journal of Medicine, 366(3), pp. 234-242.
- Karnezis, A.N. et al. (2019) ‘DICER1 and FOXL2 mutation status correlates with clinicopathologic features in ovarian Sertoli-Leydig cell tumors’, American Journal of Surgical Pathology, 43(5), pp. 628-638.
- Gui, T. et al. (2012) ‘A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors’, Gynecologic Oncology, 127(2), pp. 384-389.
- Gouy, S. et al. (2019) ‘Results from a monocentric long-term analysis of 23 patients with ovarian Sertoli-Leydig cell tumors’, The Oncologist, 24(5), pp. 702-709.
- Ray-Coquard, I. et al. (2018) ‘Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 29(Suppl 4), pp. iv1-iv18.
- Schultz, K.A.P. et al. (2018) ‘DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies’, Clinical Cancer Research, 24(10), pp. 2251-2261.
- Nelson, A.T. et al. (2025) ‘Prognostic significance of germline DICER1 pathogenic or likely pathogenic variants in outcomes of ovarian Sertoli-Leydig cell tumor’, JCO Precision Oncology, 9, e2400902.
- Schultz, K.A.P. et al. (2014) ‘DICER1-related tumor predisposition’, in Adam, M.P. et al. (eds) GeneReviews. Seattle: University of Washington. Available at: https://www.ncbi.nlm.nih.gov/books/NBK196157/ (Accessed: October 2026).
Prepared by the editorial team, October 2026.